~~<i id='A438DC7109'><strike id='A438DC7109'><tt id='A438DC7109'><pre id='A438DC7109'></pre></tt></strike></i>~~

Home» focus» knowledge

knowledge

author：knowledge 2025-09-27 19:56:31 Page View：3

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 'CMA Fest' 2023: How to watch, who is performing and more
Next article： Alkermes shareholders re

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

Sanofi seeks simpler, safer CRISPR sickle cell cure

RubyWallauforSTATSanofiwilllicenseanewCRISPRenzymefromthestartupScribeTherapeuticsinabidtobethefirst

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida

'CMA Fest' 2023: How to watch, who is performing and more

3:13LukeCombsisshownatCMAFest2023,onJune8,2023,inNashville,Tenn.|RebaMcEntireandMirandaLambertaresho